Drug intelligence / Profile preview

GXHPC1

Development stage: Phase 2
Lead developer: Gwo Xi Stem Cell Applied Technology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intrahepatic

Overview

GXHPC1 is an autologous adipose-derived stem cell (ADSC) therapy developed by Gwo Xi Stem Cell Applied Technology for the treatment of liver cirrhosis. The therapy involves the isolation and expansion of mesenchymal stem cells from the patient's own adipose tissue, which are then administered via intra-hepatic artery injection. GXHPC1 is designed to promote hepatic tissue repair, reduce fibrotic scarring, and improve overall liver function by leveraging the regenerative and immunomodulatory properties of stem cells. It has been evaluated in clinical trials to assess its safety and efficacy in patients with advanced liver disease.

Other names: autologous adipose-derived stem cellsADSCs

Beyond the preview

Go deeper on GXHPC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GXHPC1.

Explore the full profile